| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Douglas B Given last filed a Form 4 in December 2024, as Director at ARWR. Douglas B Given's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Douglas B Given's trades have earned a middling insider score of 66/100 across 9 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +0.8%.
At the last filing, the largest reported position was 124,167 shares of ARWR. The ARWR filings lean toward selling, a net 181,378 shares.
Douglas B Given has 29 Form 4 filings on record from March 2015 to December 2024, all as Director at Arrowhead Pharmaceuticals (ARWR), 2015–2024.
The 53 reported transactions were 21 open-market sales, 16 gifts, 10 stock awards and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $43K and 17 sales worth about $5.3M.
The only open-market purchase was 655 shares of ARWR at an average $66.37 on December 28, 2021, about $43K. Twelve months later ARWR was down 43%.
The largest open-market sale was 68,000 shares of ARWR at an average $19.20 on February 26, 2019, about $1.3M.
2 of the 3 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
Shares as reported in the last Form 4 for each company; the most recent is from December 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell10b5-1 | 5,547 | $21.91 | $121,555.88 | -4.3% | -30.0% | +191.0% | |
| Jan 11, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell10b5-1 | 2,911 | $38.06 | $110,788.36 | -2.2% | -32.3% | -50.7% | |
| May 5, 2023 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 6,500 | $40.90 | $265,850.00 | -5.2% | -21.9% | -40.9% | |
| Feb 27, 2023 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 875 | $32.62 | $28,542.50 | -6.3% | +0.6% | -4.4% | |
| Dec 28, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Buy | 655 | $66.37 | $43,472.35 | +0.6% | -32.2% | -43.1% | |
| Sep 9, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 5,000 | $65.24 | $326,200.00 | -4.4% | +13.3% | -40.9% | |
| Jun 22, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 4,500 | $89.21 | $401,445.00 | -3.8% | -29.8% | -64.5% | |
| Feb 22, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 1,125 | $88.73 | $99,821.25 | -7.5% | -12.0% | -49.3% | |
| Jan 15, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 3,000 | $83.28 | $249,840.00 | -19.4% | - | - | |
| Jan 4, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 4,000 | $76.08 | $304,320.00 | -3.2% | - | - |